Ad Header



The Pulse of the Pharmaceutical Industry

  • Filter By Category

  • Filter By Author

FDA approves growth hormone deficiency test

Canada’s Aeterna Zentaris Inc. said the U.S. FDA approved its oral test to diagnose adult growth hormone deficiency.

Read More »

FDA Approves Genentech’s Perjeta for Adjuvant Treatment of Specific Type of Early Breast Cancer

Genentech announced that the U.S. FDA approved Perjeta (pertuzumab), in combination with Herceptin (trastuzumab) and chemotherapy (the Perjeta-based regimen), for adjuvant treatment of HER2-positive early breast cancer at high risk of recurrence.

Read More »

Bristol-Myers Squibb Receives FDA Approval for Opdivo as Adjuvant Therapy in Patients with Completely Resected Melanoma with Lymph Node Involvement or Metastatic Disease

Bristol-Myers Squibb Company announced that the U.S. Food and Drug Administration approved Opdivo (nivolumab) injection for intravenous use for the adjuvant treatment of patients with melanoma with involvement of lymph nodes or metastatic disease who have undergone complete resection.

Read More »

Three Hottest Areas of Drug Development to Keep an Eye on in 2018

The last several years has shown a particular focus on immuno-oncology therapies, probably as close to miracle cures as anything seen in recent years. Arpita Dutt, writing for Zacks, predicts what the three hot areas for approvals are likely to be in 2018.

Read More »

France fines J&J 25 million euros over painkiller patch

France’s competition authority fined U.S. healthcare group Johnson & Johnson 25 million euros ($29.6 million) after it ruled the company had deliberately slowed market access to generic copies of its painkiller Durogesic.

Read More »

Gene therapy developer Orchard Therapeutics raises $110 million

Orchard Therapeutics said it raised $110 million in the second round of funding as the drug developer looks to launch its gene therapy to treat a rare inherited disorder and beef up manufacturing facilities.

Read More »

FDA to review Samsung Bioepis’ Herceptin copy

South Korea’s Samsung Bioepis said the U.S. FDA accepted for review its copy of Roche’s blockbuster breast cancer drug Herceptin for potential approval.

Read More »

FDA approves NDA for Prexxartan

Carmel Biosciences Inc. received final approval of its New Drug Application from the U.S. Food and Drug Administration for Prexxartan (valsartan) oral solution.

Read More »

Pfizer, Exelixis cancer drugs get FDA approval

Cancer treatments from Pfizer Inc. and Exelixis Inc. won expanded approval from the U.S. FDA for use in previously untreated patients.

Read More »

Biogen and Ionis Enter into New Collaboration to Identify Novel Therapies for the Treatment of Spinal Muscular Atrophy

Biogen and Ionis Pharmaceuticals announced that they entered into a new collaboration agreement to identify new antisense oligonucleotide drug candidates for the treatment of spinal muscular atrophy (SMA).

Read More »

DiCE Molecules Forges Multi-Year Research Deal with Genentech

A little less than two years after tying up a multi-billion deal with Sanofi, DiCE Molecules scored another collaborative deal. The Bay Area company inked a multi-year collaborative agreement with Genentech to discover new small molecules.

Read More »

Shire’s Hunter Syndrome Treatment Fails Study Goals

Shire’s experimental treatment SHP609 to address cognitive impairment in pediatric patients diagnosed with the rare disease known as Hunter syndrome failed a key trial.

Read More »

FDA approves Spark Therapeutics’ gene therapy

The FDA approved Spark Therapeutics’ treatment for a rare form of blindness, marking the first time the U.S. regulatory agency approved a gene therapy for an inherited disease.

Read More »

Chocolate makers innovate to entice health-conscious consumers

The world’s largest chocolate makers are looking for ways to keep increasingly health-conscious consumers coming back for more.

Read More »

Humana, private equity firms buy Kindred Healthcare for $810 million

U.S. health insurer Humana Inc. and two private equity firms agreed to buy home healthcare and long-term care operator Kindred Healthcare Inc. for about $810 million, the latest expansion by an American health insurer into patient care.

Read More »

Dr. Reddy’s resolves U.S. probe over drug packagingp

Dr. Reddy’s Laboratories will pay $5 million to resolve claims that the Indian company sold prescription drugs in the U.S. in packaging not tested for child safety.

Read More »

Aerie’s glaucoma treatment gets early FDA approval

The FDA approved Aerie Pharmaceuticals Inc.’s eyedrop Rhopressa as a treatment for glaucoma, two months ahead of the expected date.

Read More »

Intouch Solutions Promotes Five Chicago Employees

Intouch Solutions, a leading marketing agency serving the pharmaceutical industry, announced the promotion of five employees in its Chicago office.

Read More »

Novartis Buys Rare Drug Voucher From Ultragenyx

Novartis picked up a priority review voucher in a $130 million deal with California-based Ultragenyx Pharmaceutical Inc. The PRV is for rare pediatric diseases.

Read More »

Boehringer Inks Deal With GlaxoSmithKline Spinout

Boehringer Ingelheim tied up a schizophrenia drug under development by Autifony Limited, a 2011 spinout of GSK, in a deal that could be worth up to about $740 million.

Read More »

Ad Right Top


Extensive pharmaceutical business and marketing intelligence. For back issues, please contact

October 2018 Focus: Top 50 Pharma, Company of the Year and more!


Ad Right Bottom